年龄与转移性黑色素瘤抗PD1治疗总生存的丹麦队列研究
该研究基于丹麦全国转移性黑色素瘤队列,评估ipilimumab(530例)或pembrolizumab(562例)治疗的疗效与年龄关系。ipilimumab组年龄对生存无影响;pembrolizumab组70–80岁患者OS和PFS显著优于更年轻患者,多因素分析中年龄为独立良好预后因素,但80岁以上患者生存未优于年轻患者,可能与合并症增加有关。
要点
- pembrolizumab治疗中70–80岁患者OS和PFS显著优于年轻患者。
- ipilimumab治疗中年龄对生存或PFS无显著影响。
- 80岁以上患者生存未优于年轻患者,或与合并症增加有关。
核心结论
- pembrolizumab治疗的转移性黑色素瘤患者中70–80岁年龄组生存率更高。
- 年龄相关免疫功能障碍似乎不负面影响转移性黑色素瘤检查点抑制剂疗效。
- 临床仍需谨慎考虑老年患者免疫相关不良事件更严重结局的风险。
研究设计与样本
- 丹麦全国转移性黑色素瘤患者队列,ipilimumab组530例,pembrolizumab组562例。
主要发现
- ipilimumab组确认已知预后生物标志物,年龄对生存或PFS无影响。
- pembrolizumab组确认已知预后生物标志物,70–80岁患者OS和PFS显著高于年轻患者。
- 以OS为终点的多因素分析中,年龄为独立良好预后生物标志物。
- 80岁以上患者生存未优于年轻患者,可能与显著合并症增加有关。
临床怎么用
- 对70–80岁转移性黑色素瘤患者使用pembrolizumab时,年龄不应作为排除治疗的依据。
- 治疗80岁以上患者前需仔细评估严重免疫相关不良事件风险及合并症情况。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PATIENTS: Age-related immune dysfunction (ARID) describes age-associated changes in immunity that may affect the efficacy of immunotherapy with checkpoint inhibitors. We evaluated the efficacy of treatment with ipilimumab (530 patients) or pembrolizumab (562 patients) in a Danish national cohort of metastatic melanoma patients. RESULTS: We confirmed known prognostic biomarkers related to treatment with ipilimumab and found no impact of age on survival or progression-free survival. In patients treated with pembrolizumab, we also confirmed known prognostic biomarkers. Overall survival (OS) and progression-free survival was significantly higher in patients aged between 70 and 80 years compared with younger patients. In multivariate analysis with OS as end-point, age was shown to be an independent good prognostic biomarker in these patients. Survival in patients aged above 80 years was not better than in younger patients, probably because of increase in significant comorbidity. CONCLUSIONS: Our analyses have revealed a higher survival rate when using drugs targeting PD1 in metastatic melanoma patients between the age of 70 and 80 years. ARID does not seem to negatively impact the efficacy of treatment with checkpoint inhibitors in metastatic melanoma patients. Despite these encouraging data for elderly patients, clinicians still need to carefully consider the higher risk of more serious outcomes of the immune-related adverse events in the elderly patient population, before deciding to treat old patients with checkpoint inhibitors.
引用
- Bastholt L, Schmidt H, Bjerregaard JK, et al. Age favoured overall survival in a large population-based Danish patient cohort treated with anti-PD1 immune checkpoint inhibitor for metastatic melanoma. Eur J Cancer. 2019. PMID: 31442816. doi:10.1016/j.ejca.2019.06.022
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。